1-[2-(4-Aminopiperidin-1-yl)ethyl]-7-methoxy-1,4-dihydro-2H-3,1-benzoxazin-2-one trifluoro acetate → 1-[2-(4-Amino-2-oxopiperidin-1-yl)ethyl]-7-methoxy-3-methylquinazoline-2,4(1H,3H)-dione
반응식
[CH3:1][O:2][C:3]1[CH:12]=[C:11]2[C:6]([C:7](=[O:31])[N:8]([CH3:30])[C:9](=[O:29])[N:10]2[CH2:13][CH2:14][N:15]2[CH2:20][CH2:19][CH:18]([NH:21]C(=O)OC(C)(C)C)[CH2:17][CH2:16]2)=[CH:5][CH:4]=1.FC(F)(F)C(O)=[O:35].NC1CCN(CCN2C3C=C(OC)C=CC=3COC2=O)CC1>>[NH2:21][CH:18]1[CH2:19][CH2:20][N:15]([CH2:14][CH2:13][N:10]2[C:11]3[C:6](=[CH:5][CH:4]=[C:3]([O:2][CH3:1])[CH:12]=3)[C:7](=[O:31])[N:8]([CH3:30])[C:9]2=[O:29])[C:16](=[O:35])[CH2:17]1참가 물질
3
반응물 2
생성물 1
실험 절차
tert-Butyl {1-[2-(7-methoxy-3-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)ethyl]piperidin-4-yl}carbamate (Intermediate 111, 350 mg, 0.83 mmol) was reacted as described for Intermediate 106. The crude trifluoro acetate of the title compound was obtained as a black oil, 395 mg. (quantitative), and used without further purification for the next step.